Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 5, Pages 467-475
Publisher
Springer Science and Business Media LLC
Online
2020-03-11
DOI
10.1007/s40265-020-01278-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
- (2019) Adrian Vella et al. Science Translational Medicine
- The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans
- (2019) Franz M. Matschinsky et al. Frontiers in Physiology
- Clinical and Enzymatic Phenotypes in Congenital Hyperinsulinemic Hypoglycemia due to Glucokinase‐activating Mutations: a report of two cases and a brief overview of literature
- (2019) Fan Ping et al. Journal of Diabetes Investigation
- TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
- (2019) Aoife Egan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
- (2018) Xiao-Xue Zhu et al. DIABETES OBESITY & METABOLISM
- Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis
- (2018) Kamlesh Khunti et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- New hope for glucokinase activators in type 2 diabetes?
- (2018) André J Scheen Lancet Diabetes & Endocrinology
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Dalong Zhu et al. Lancet Diabetes & Endocrinology
- Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis
- (2018) Pomme I. H. G. Simons et al. PLoS One
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Regulation of hepatic glucose metabolism in health and disease
- (2017) Max C. Petersen et al. Nature Reviews Endocrinology
- Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment
- (2016) Shazhan Amed et al. Canadian Journal of Diabetes
- The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
- (2016) Stanley S. Schwartz et al. DIABETES CARE
- Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
- (2016) Amy K. Rines et al. NATURE REVIEWS DRUG DISCOVERY
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Glucokinase regulatory protein
- (2015) Anne Raimondo et al. CURRENT OPINION IN LIPIDOLOGY
- Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation
- (2015) Ali J. Chakera et al. DIABETES CARE
- AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes
- (2015) L. Katz et al. DIABETES OBESITY & METABOLISM
- Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus
- (2015) Jianguo Zhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
- (2015) Martijn C.G.J. Brouwers et al. TRENDS IN MOLECULAR MEDICINE
- Novel therapeutics for type 2 diabetes: insulin resistance
- (2014) Q.-A. Altaf et al. DIABETES OBESITY & METABOLISM
- A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014
- (2014) Kevin J Filipski et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Lessons from glucokinase activators: the problem of declining efficacy
- (2014) Loranne Agius EXPERT OPINION ON THERAPEUTIC PATENTS
- Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia
- (2014) Anna M. Steele et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Characterization of a Novel Glucokinase Activator in Rat and Mouse Models
- (2014) Min Lu et al. PLoS One
- Present status of clinical deployment of glucokinase activators
- (2014) Akinobu Nakamura et al. Journal of Diabetes Investigation
- Type 2 Diabetes and Congenital Hyperinsulinism Cause DNA Double-Strand Breaks and p53 Activity in β Cells
- (2013) Sharona Tornovsky-Babeay et al. Cell Metabolism
- Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
- (2013) A. Kiyosue et al. DIABETES OBESITY & METABOLISM
- Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
- (2013) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes
- (2013) Jeffrey A Pfefferkorn Expert Opinion on Drug Discovery
- Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase
- (2013) J. M. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
- (2013) Franz M. Matschinsky TRENDS IN PHARMACOLOGICAL SCIENCES
- Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes
- (2012) Catherine Arden et al. BIOCHEMICAL JOURNAL
- Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation
- (2012) Nicolai M. Doliba et al. DIABETES OBESITY & METABOLISM
- Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions
- (2012) A. Nakamura et al. DIABETOLOGIA
- Elevated Glucose Represses Liver Glucokinase and Induces Its Regulatory Protein to Safeguard Hepatic Phosphate Homeostasis
- (2011) C. Arden et al. DIABETES
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
- (2011) G. E. Meininger et al. DIABETES CARE
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function
- (2011) Akinobu Nakamura et al. Journal of Diabetes Investigation
- Novel glucokinase activators: a patent review (2008 – 2010)
- (2010) Ramakanth Sarabu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Exploring thein VivoMechanisms of Action of Glucokinase Activators in Type 2 Diabetes
- (2010) Gianluca Perseghin JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
- (2010) Riccardo C. Bonadonna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Glucokinase and molecular aspects of liver glycogen metabolism
- (2008) Loranne Agius BIOCHEMICAL JOURNAL
- Impact of Small-Molecule Glucokinase Activator on Glucose Metabolism and β-Cell Mass
- (2008) Akinobu Nakamura et al. ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started